Immunome, Inc. (NASDAQ:IMNM) Director Purchases $97,580.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime bought 7,000 shares of the company’s stock in a transaction on Friday, August 16th. The shares were bought at an average price of $13.94 per share, for a total transaction of $97,580.00. Following the completion of the acquisition, the director now directly owns 16,615 shares in the company, valued at approximately $231,613.10. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

Jean Jacques Bienaime also recently made the following trade(s):

• On Tuesday, May 21st, Jean Jacques Bienaime bought 2,000 shares of Immunome stock. The shares were bought at an average price of $13.57 per share, for a total transaction of $27,140.00.

Immunome Stock Down 0.1 %

Shares of IMNM opened at $15.20 on Thursday. The stock has a market capitalization of $911.53 million, a P/E ratio of -2.01 and a beta of 1.78. Immunome, Inc. has a twelve month low of $6.13 and a twelve month high of $30.96. The company has a 50 day moving average of $13.52 and a 200-day moving average of $17.44.

Hedge Funds Weigh In On Immunome

Several hedge funds have recently made changes to their positions in IMNM. Cerity Partners LLC bought a new position in shares of Immunome during the 4th quarter worth approximately $656,000. Jump Financial LLC bought a new position in shares of Immunome in the fourth quarter valued at $172,000. Mayo Clinic bought a new position in shares of Immunome in the fourth quarter valued at $1,161,000. Avidity Partners Management LP bought a new position in shares of Immunome in the fourth quarter valued at $14,268,000. Finally, Clear Creek Financial Management LLC bought a new position in shares of Immunome in the first quarter valued at $547,000. 44.58% of the stock is owned by institutional investors.

Analyst Ratings Changes

IMNM has been the topic of several research analyst reports. JPMorgan Chase & Co. initiated coverage on shares of Immunome in a report on Tuesday, April 30th. They set an “overweight” rating and a $24.00 target price on the stock. Wedbush restated an “outperform” rating and set a $33.00 target price on shares of Immunome in a report on Tuesday, August 13th. Finally, Piper Sandler dropped their target price on shares of Immunome from $27.00 to $23.00 and set an “overweight” rating on the stock in a report on Tuesday, August 13th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Immunome has a consensus rating of “Buy” and an average target price of $29.00.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.